Literature DB >> 9925537

Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin.

M I García-Arata1, F Baquero, L de Rafael, C Martín de Argila, J P Gisbert, F Bermejo, D Boixeda, R Cantón.   

Abstract

Mutations conferring resistance to erythromycin or clarithromycin in Helicobacter pylori were studied. Mutation A2142G was consistently associated with clarithromycin MIC of > 256 micrograms/ml, whereas mutants carrying A2143G had MICs ranging from < or = 0.016 to > 256 micrograms/ml, suggesting that additional factors account for the observed multiple levels of resistance to clarithromycin.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9925537      PMCID： PMC89082     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.

Authors:  D Y Graham; W A de Boer; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

2.  A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Authors:  G G Stone; D Shortridge; J Versalovic; J Beyer; R K Flamm; D Y Graham; A T Ghoneim; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori.

Authors:  F Szczebara; L Dhaenens; P Vincent; M O Husson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

4.  Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.

Authors:  H X Xia; M Buckley; C T Keane; C A O'Morain
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

Review 5.  Erythromycin resistance by ribosome modification.

Authors:  B Weisblum
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 6.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  Y Glupczynski; M Labbé; W Hansen; F Crokaert; E Yourassowsky
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

9.  Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

10.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790
View more
  13 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori.

Authors:  Christophe Burucoa; Cédric Landron; Martine Garnier; Jean-Louis Fauchère
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Antibiotic resistance of Helicobacter pylori strains in Japanese children.

Authors:  Seiichi Kato; Shigeru Fujimura; Hirokazu Udagawa; Toshiaki Shimizu; Shunichi Maisawa; Kyoko Ozawa; Kazuie Iinuma
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance.

Authors:  J M Bartkus; B A Juni; K Ehresmann; C A Miller; G N Sanden; P K Cassiday; M Saubolle; B Lee; J Long; A R Harrison; J M Besser
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.

Authors:  Vincenzo De Francesco; Angelo Zullo; Cesare Hassan; Floriana Giorgio; Rosa Rosania; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2011-06-15

6.  New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates.

Authors:  Carla Fontana; Marco Favaro; Silvia Minelli; Anna Angela Criscuolo; Antonio Pietroiusti; Alberto Galante; Cartesio Favalli
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 7.  Biofilms and Helicobacter pylori: Dissemination and persistence within the environment and host.

Authors:  Steven L Percival; Louise Suleman
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

8.  Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation.

Authors:  K Trebesius; K Panthel; S Strobel; K Vogt; G Faller; T Kirchner; M Kist; J Heesemann; R Haas
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

9.  Molecular Detection of Antibiotic Resistance in South African Isolates of Helicobacter pylori.

Authors:  Nicoline F Tanih; Roland N Ndip
Journal:  Gastroenterol Res Pract       Date:  2013-04-24       Impact factor: 2.260

10.  Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations.

Authors:  Hideo Yonezawa; Takako Osaki; Tomoko Hanawa; Satoshi Kurata; Kuniyasu Ochiai; Shigeru Kamiya
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.